Increased Interleukin-17F is Associated with Elevated Autoantibody Levels and More Clinically Relevant Than Interleukin-17A in Primary Sjögren’s Syndrome

Yuzhou Gan,1,2,3 Xiaozhen Zhao,1,2,3 Jing He,1,2,3 Xu Liu,1,2,3 Yun Li,1,2,3 Xiaolin Sun,1,2,3 and Zhanguo Li1,2,3

1Department of Rheumatology and Immunology, Peking University People’s Hospital and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China
2Center of Clinical Immunology, Peking University, Beijing 100044, China
3Peking-Tsinghua Center for Life Sciences, Beijing, China

Correspondence should be addressed to Xiaolin Sun; sunxiaolin_sxl@126.com and Zhanguo Li; li99@bjmu.edu.cn

Received 15 August 2016; Revised 4 November 2016; Accepted 9 November 2016; Published 22 January 2017

Academic Editor: Jacek Tabarkiewicz

Copyright © 2017 Yuzhou Gan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Th17 related immune response is pathogenic in primary Sjögren’s syndrome (pSS). However, the role of IL-17F, one potent inflammatory member of IL-17 family cytokines in pSS, has not been specifically defined. We recruited one hundred and nine pSS patients and forty-two healthy controls and their serum levels of IL-17A and IL-17F were determined by multiplex cytokine assays. White blood cell, red blood cell, neutrophil, lymphocyte, IgM, IgG, C3, C4, RF, ANA, anti-SSA antibody, and anti-SSB antibody were measured by standard laboratory techniques. EULAR Sjögren’s syndrome disease activity index (ESSDAI) score was also evaluated accordingly. We found that IL-17F was significantly increased in pSS patients. Elevated levels of IL-17F were associated with increased IgG and IgM, higher titers of ANA and anti-SSA antibodies, and reduction of C3 and C4. Patients with higher disease activity also showed higher serum IL-17F levels. However, serum IL-17A was only increased in patients with longer disease duration and showed few correlation with clinical and laboratory features in pSS patients. In conclusion, IL-17F was correlated with increased autoantibody levels and disease activity in pSS and is more clinically relevant than IL-17A.

1. Introduction

Primary Sjögren’s syndrome (pSS) is an autoimmune disease with exocrine gland dysfunction and at least one-third of pSS patients experience multiorgan involvement [1]. Historically, pSS was thought to be a Th1 driven disease due to the predominance of CD4+ T cells and their product, interferon-γ, in target organs and peripheral blood from these patients [2]. However, accumulating studies in human and animal models have revealed that Th17 immune response and IL-17 family cytokines also play a vital role in pSS [3–11].

IL-17A, commonly referred to as IL-17, is involved in normal physiological processes [12] and is also a leading pathogenic cytokine in a wide range of pathologic conditions, including cancer and autoimmune disorders, due to its strong proinflammatory effects [13]. Besides IL-17A, there are five other members structurally related to IL-17A in the IL-17 family, which are IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and IL-17F. These molecules bear 20%–50% homology to IL-17A, especially within the C-terminal region [12].

IL-17F, first identified in 2001, shares the highest homology with IL-17A and is encoded by the Il17f gene in the same chromosome region of Il17a [14, 15]. IL-17F is mainly expressed by Th17 and IL-17-producing γδT cells [15]. Furthermore, IL-17F and IL-17A bind the same receptor complexes [16] and have similar functions in terms of induction of chemokines and cytokines [17] and activation of neutrophils and lymphocytes [18]. Although IL-17A and IL-17F are highly homologous, they do not always function in the same manner [19]. IL-17F is involved more in tissue inflammation and is shown to be a stronger neutrophil-recruiting cytokine than IL-17A [20]. In some diseases, such as psoriasis [21, 22] and
asthma [23], IL-17F plays a more prominent role. However, there are no studies focusing on the clinical relevance and pathogenic roles of IL-17F in pSS and many other autoimmune diseases.

In the present study, we determined the serum levels of IL-17F in pSS patients comparing with healthy controls and analyzed their clinical relevance in pSS. It showed that increased IL-17F was positively associated with autoantibody levels and disease activity in pSS and might play a more dominant role in the pathogenesis of pSS in comparison to IL-17A.

2. Methods

2.1. Patients and Controls. We recruited 109 patients from the Department of Rheumatology, Peking University People's Hospital, Beijing, China, during January 2014 and December 2015. All were diagnosed with pSS and fulfilled the 2002 American-European Consensus Group Classification Criteria [24]. The exclusion criteria are (1) any other systemic autoimmune diseases; (2) severe infection, malignant tumor, severe organ dysfunction, or any other life-threatening conditions. We also recruited 42 healthy controls (HC) from the health examination center of the same hospital, with age and sex matched. All of them were excluded from any autoimmune diseases. The study was approved by the Ethics Committee of Peking University People's Hospital (Approval number 2015PHB219-01). All participants of this study had been informed and signed the consent for participation in this study.

2.2. Clinical and Laboratory Data. All patients underwent extensive clinical medical examinations and serological evaluations, including disease duration, lymphadenectomy, splenomegaly, white blood cell (WBC) count, neutrophil granulocyte count, lymphocyte count, red blood cell (RBC) count, hemoglobin (Hb), platelet count (PLT), immunoglobulin M (IgM), immunoglobulin G (IgG), complement 3 (C3), complement 4 (C4), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), antinuclear antibodies (ANA), and EULAR Sjögren syndrome disease activity index (ESSDAI) score [25]. Besides, joint involvement is defined as the existence of arthralgia or arthritis; pulmonary involvement is defined by the presence of respiratory symptoms (mainly persistent cough and/or dyspnoea) or altered pulmonary diagnostic tests (including pulmonary function tests (PFTs) and/or CT scan) [26].

2.3. Serum Samples. 3 mL of peripheral venous blood was collected from both groups and waited to clot in room temperature for 2 hours. Samples were then centrifuged for 15 minutes at 3000 rpm under 4°C. The serum was then collected in polypropylene microfuge tubes and stored at −80°C for further analysis.

2.4. Measurement of Anti-SSA Antibody and Anti-SSB Antibody. Serum levels of anti-SSA antibody and anti-SSB antibody were measured by anti-SSA antibody IgG ELISA kit (Euroimmun) and anti-SSB antibody IgG ELISA kit (Euroimmun). The procedure was according to the manufacturer's instructions. Concentrations of anti-SSA antibody and anti-SSB antibody were determined by a linear standard curve.

2.5. Measurement of Th-17 Associated Cytokines. Serum levels of IL-17A and IL-17F were measured by MILLIPLEX MAP Human Th17 magnetic bead panel kits (Millipore, USA). The measurement procedure was based on the Luminex xMAP technology (EMD Millipore, USA), following the manufacturer's instructions. Interpanel and intra-assay control plasma samples were included to ensure consistency across panels. Data were read on the Luminex MAGPIX machine (Luminex Corporation) and analyzed using MILLIPLEX Analyst 5.1 software (Millipore). Concentrations of cytokines were calculated using a cubic standard curve.

2.6. Statistical Analysis. Data analyses were performed using SPSS 19.0 for Windows. The distribution of numerical data was evaluated by Shapiro-Wilk test. Numerical data with normal distribution were expressed as the mean ± standard and differences between two groups were analyzed by independent t-test. Numerical data with skewed distribution were expressed as median (P25, P75) and differences between two groups were analyzed by Mann-Whitney test. Ranked data were expressed as percentage and differences between two groups were analyzed by chi-square test. Correlations between variables were determined by Spearman's correlation coefficient. The cut-off values of IL-17A and IL-17F were determined by receiver operating characteristics (ROC) curve analysis. P < 0.05 was considered statistically significant.

3. Results

3.1. Characteristics of pSS Patients and Controls. A total of 109 pSS inpatients and 42 healthy controls with matched age and gender were included in this study. The mean age of 109 pSS patients at the time of our study was 55.72 ± 14.64 years (range 12–76) and the mean disease duration was 10.39 years ranging from 2 months to 40 years. Demographic, clinical, and laboratory features of pSS patients and healthy controls are shown in Table 1. Anti-SSA antibody and anti-SSB antibody were positive in 68 (62.85%) and 60 (55.06%), respectively. 62 pSS patients (56.88%) showed moderate to high disease activity.

3.2. Serum Levels of IL-17F Were Significantly Elevated in pSS Patients instead of IL-17A. As shown in Figure 1, the serum level of IL-17F (Figure 1(b) 20.35 ± 20.66 versus 9.56 ± 3.20, P = 0.001) was significantly higher in pSS patients comparing to healthy controls, while serum level of IL-17A (Figure 1(a) 10.37 ± 3.95 versus 10.29 ± 1.87, P = 0.05) did not show statistical significance in the two groups. According to the cut-off values for identification of overexpressed serum IL-17A and IL-17F, 109 pSS patients were grouped into IL-17F-elevated group (IL-17F ≥ 15.44 pg/mL, n = 43) and IL-17F-normal group (IL-17F < 15.44 pg/mL, n = 66) and
Table 1: Characteristics of the studied 109 pSS patients and 42 healthy controls.

| Clinical characteristics | pSS               | Controls          | t/χ²   | P     |
|--------------------------|-------------------|-------------------|--------|-------|
| Age (years)              | 55.72 ± 14.64     | 55.12 ± 13.17     | 0.231  | 0.818 |
| Sex (F:M)                | 105:4             | 40:2              |        |       |
| WBC (×10^3/L)            | 4.77 ± 2.10       | —                 | —      | —     |
| Neutrophils (×10^9/L)    | 3.04 ± 1.89       | —                 | —      | —     |
| RBC (×10^12/L)           | 3.74 ± 0.62       | —                 | —      | —     |
| Hb (g/L)                 | 116.17 ± 18.19    | —                 | —      | —     |
| PLT (×10^3/L)            | 143.28 ± 70.95    | —                 | —      | —     |
| IgA (g/L)                | 3.37 ± 1.77       | —                 | —      | —     |
| IgG (g/L)                | 19.44 ± 9.45      | —                 | —      | —     |
| IgM (g/L)                | 1.68 ± 1.33       | —                 | —      | —     |
| C3 (g/L)                 | 0.90 ± 0.21       | —                 | —      | —     |
| C4 (g/L)                 | 0.19 ± 0.07       | —                 | —      | —     |
| ESR (mm/h)               | 32.82 ± 30.12     | —                 | —      | —     |
| RF (IU/mL)               | 178.65 ± 295.04   | —                 | —      | —     |
| ANA ≥ 1:320              | 56.31%            | —                 | —      | —     |
| Anti-SSA ≥ 200 RU/mL     | 62.85%            | —                 | —      | —     |
| Anti-SSB ≥ 20 RU/mL      | 55.06%            | —                 | —      | —     |
| ESSDAI ≥ 5               | 56.88%            | —                 | —      | —     |

*1 patient did not have the data of C3 and C4.
**4 patients did not have the data of ANA.

Figure 1: Comparison of serum levels of IL-17A and IL-17F between pSS patients and HC. (a) Serum IL-17A levels were not significantly elevated in pSS patients versus HC. (b) Serum IL-17F levels were significantly elevated in pSS patients versus HC.

3.3. Increased Serum Levels of IL-17F Were Associated with Elevated Autoantibody Level in pSS. As shown in Table 2, in pSS patients, IL-17F were positively correlated with RF (r = 0.481, P < 0.001) and anti-SSA antibodies (r = 0.236, P = 0.014). However, serum level of IL-17A was only positively correlated with RF (r = 0.234, P = 0.015). Besides, we divided pSS patients into the elevated group and the normal group, respectively, according to the cut-off values. As shown in Table 3, patients with higher serum levels of IL-17F showed elevated RF (205.00 (42.00, 1689.50) versus 20.00 (20.00, 69.50), P = 0.001), higher titers of anti-SSA antibodies (1484.99 (178.52, 1689.50) versus 454.25 (18.89, 1386.96), P = 0.002), and higher percentage of ANA ≥ 1:320 (70% versus 46.15%, P = 0.026), but patients with higher serum levels of IL-17A only showed higher titers of RF (345.50 (24.28, 573.25) versus 27.35 (20.00, 193.50), P = 0.016) and higher percentage of ANA ≥ 1:320 (72.73% versus 31.91%, P = 0.017).

Significantly elevated IL-17F levels were also observed in pSS patients with increased autoantibody levels compared...
Table 2: Correlation of serum IL-17F and IL-17A with clinical and laboratory features of pSS patients.

| Clinical manifestations and laboratory features | IL-17F | | IL-17A | |
|-----------------------------------------------|--------|---|--------|---|
| | Spearman $r$ | $P$ | Spearman $r$ | $P$ |
| WBC | −0.146 | 0.129 | −0.135 | 0.162 |
| Neutrophils | −0.116 | 0.23 | −0.086 | 0.376 |
| RBC | 0.056 | 0.561 | −0.029 | 0.765 |
| Hb | 0.01 | 0.918 | −0.067 | 0.491 |
| PLT | 0.062 | 0.521 | 0.039 | 0.686 |
| IgA | 0.015 | 0.88 | −0.055 | 0.572 |
| IgG | 0.226 | 0.018 | −0.039 | 0.684 |
| IgM | 0.215 | 0.025 | 0.107 | 0.27 |
| C3 | −0.284 | 0.003 | −0.304 | 0.001 |
| C4 | −0.235 | 0.014 | −0.179 | 0.064 |
| ESR | −0.054 | 0.574 | 0.035 | 0.72 |
| RF | 0.481 | <0.001 | 0.234 | 0.015 |
| Anti-SSA | 0.236 | 0.014 | −0.056 | 0.565 |
| Anti-SSB | 0.039 | 0.691 | −0.148 | 0.125 |

Table 3: Clinical and laboratory characteristics of pSS patients with the elevated and normal levels of serum IL-17F and IL-17A.

| Clinical and laboratory parameters | <15.44 pg/mL $(n = 66)$ | ≥15.44 pg/mL $(n = 43)$ | $t/u/\chi^2$ | $P$ | <13.8 pg/mL $(n = 97)$ | ≥13.8 pg/mL $(n = 12)$ | $t/u/\chi^2$ | $P$ |
|-----------------------------------|--------------------------|--------------------------|--------------|------|--------------------------|--------------------------|--------------|------|
| Lymphadenectasis                  | 15 (22.73%)              | 10 (23.26%)              | 0.004        | 0.949 | 20 (20.62%)              | 5 (41.67%)               | 2.677        | 0.102 |
| Splenomegaly                      | 8 (12.12%)               | 5 (11.63%)               | 0.006        | 0.938 | 11 (11.34%)              | 2 (16.67%)               | —            | 0.634 |
| Joint involvement                 | 6 (9.09%)                | 6 (13.95%)               | 0.628        | 0.535 | 12 (12.37%)              | 0                        | —            | 0.354 |
| Lung involvement                  | 32 (48.48%)              | 20 (46.51%)              | 0.041        | 0.84  | 48 (48.98%)              | 4 (33.33%)               | —            | 0.366 |
| WBC $(\times 10^9/L)$             | 4.39 (3.59, 6.44)        | 3.72 (3.02, 5.00)        | 1.975        | 0.048 | 4.20 (3.14, 5.95)        | 4.26 (3.71, 5.66)        | 0.239        | 0.812 |
| Neutrophils $(\times 10^9/L)$     | 2.55 (1.79, 4.45)        | 2.18 (1.61, 3.41)        | 2.309        | 0.023 | 2.39 (1.69, 3.82)        | 2.31 (1.71, 3.97)        | 0.254        | 0.8   |
| RBC $(\times 10^9/L)$             | 3.71 ± 0.65              | 3.77 ± 0.57              | −0.543       | 0.588 | 3.74 ± 0.62              | 3.71 ± 0.69              | 0.167        | 0.867 |
| Hb $(g/L)$                        | 11717 ± 17.28            | 114.63 ± 19.61           | 0.71         | 0.479 | 116.94 ± 16.81           | 109.93 ± 27.09           | 1.263        | 0.209 |
| PLT $(\times 10^9/L)$             | 142.59 ± 78.08           | 144.33 ± 59.23           | −0.124       | 0.901 | 142.79 ± 71.57           | 147.17 ± 65.58           | −0.201       | 0.841 |
| IgA $(g/L)$                       | 2.78 (2.07, 4.21)        | 3.25 (2.27, 4.25)        | −0.682       | 0.495 | 3.37 ± 1.73              | 3.45 ± 2.17              | −0.044       | 0.965 |
| IgG $(g/L)$                       | 17.48 ± 9.19             | 22.46 ± 9.15             | −2.2772      | 0.007 | 19.30 ± 9.56             | 20.58 ± 8.85             | −0.842       | 0.4   |
| IgM $(g/L)$                       | 1.13 (0.78, 2.03)        | 1.43 (1.07, 2.18)        | −1.779       | 0.075 | 1.62 ± 1.30              | 2.21 ± 1.52              | −1.965       | 0.049 |
| C3 $(g/L)$                        | 0.94 ± 0.23              | 0.85 ± 0.17              | 2.228        | 0.028 | 0.92 ± 0.22              | 0.81 ± 0.13              | 2.093        | 0.036 |
| C4 $(g/L)$                        | 0.19 ± 0.07              | 0.18 ± 0.06              | 1.355        | 0.178 | 0.19 ± 0.06              | 0.16 ± 0.08              | 1.336        | 0.181 |
| ESR (mm/h)                        | 32.33 ± 29.44            | 33.56 ± 31.47            | −0.207       | 0.837 | 32.06 ± 29.68            | 38.92 ± 34.28            | −0.742       | 0.46  |
| RF (IU/mL)                        | 20 (20, 69.50)           | 205.00 (42.00, 462.00)   | −3.594       | 0.001 | 27.35 (20.00, 193.50)    | 345.00 (24.28, 573.25)   | −2.419       | 0.016 |
| ANA ≥ 1: 320                      | 30 (46.15%)              | 28 (70%)                 | 5.695        | 0.026 | 30 (31.91%)              | 8 (72.73%)               | 6.948        | 0.017 |
| Anti-SSA (RU/mL)                  | 454.25 (18.89, 1386.96)  | 1484.99 (178.52, 1689.50)| −3.225       | 0.002 | 914.45 (66.15, 1618.97)  | 176.97 (3.91, 1567.35)   | 1.081        | 0.282 |
| Anti-SSB (RU/mL)                  | 15.51 (2.16, 199.63)     | 15.74 (4.05, 250.09)     | −0.967       | 0.337 | 17.19 (2.33, 228.81)     | 7.19 (4.27, 191.45)      | 0.513        | 0.609 |
| ESSDAI ≥ 5                        | 33 (50%)                 | 30 (69.77%)              | 4.171        | 0.041 | 55 (56.70%)              | 8 (66.67%)               | 0.435        | 0.51  |
Table 4: Serum levels of IL-17A and IL-17F in the presence and absence of clinical and laboratory manifestations of pSS patients.

| Clinical and laboratory parameters | IL-17F (pg/mL) | IL-17A (pg/mL) |
|-----------------------------------|---------------|---------------|
|                                   | Presence      | Absence       | Presence      | Absence       |
| Lymphadenecesis                   | 12.68 (8.69, 20.08) | 13.09 (10.00, 21.54) | -0.519 | 0.604 | 9.13 (7.88, 13.38) | 9.75 (8.51, 10.36) | -0.268 | 0.789 |
| Splenomegaly                      | 12.68 (9.22, 22.69) | 13.09 (9.60, 20.26) | 0.164 | 0.87 | 9.75 (9.13, 11.59) | 9.44 (7.88, 10.36) | 1.618 | 0.106 |
| Joint involvement                 | 14.89 (9.87, 22.81) | 12.68 (9.73, 19.98) | 0.581 | 0.561 | 7.88 (7.88, 9.13) | 9.75 (8.51, 10.98) | -2.443 | 0.015 |
| Lung involvement                  | 12.81 (10.00, 19.42) | 13.22 (9.47, 27.27) | -0.525 | 0.6 | 9.44 (8.51, 10.59) | 9.75 (8.88, 10.98) | -0.091 | 0.927 |
| WBC ≤ 3.5 × 10^9/L               | 17.17 (9.60, 34.15) | 12.68 (9.73, 19.42) | 1.535 | 0.125 | 9.75 (9.13, 11.36) | 9.13 (7.88, 10.67) | 1.128 | 0.259 |
| Neutrophils ≤ 18 × 10^9/L         | 15.16 (8.69, 27.27) | 12.68 (10.00, 19.42) | 0.521 | 0.602 | 9.75 (8.51, 10.97) | 9.44 (7.88, 10.90) | 0.386 | 0.998 |
| RBC ≤ 3.5 × 10^{12}/L             | 13.23 (9.47, 28.07) | 12.95 (10.00, 18.85) | 0.747 | 0.455 | 9.44 (7.88, 10.51) | 9.75 (7.88, 11.21) | -0.679 | 0.497 |
| Hb ≤ 110 g/L                      | 12.14 (8.95, 17.99) | 13.77 (9.87, 28.88) | -1.315 | 0.189 | 9.75 (7.88, 10.98) | 9.59 (7.88, 10.51) | 0.199 | 0.843 |
| PLT ≤ 100 × 10^9/L                | 12.95 (9.47, 22.07) | 13.22 (10.00, 20.62) | -0.363 | 0.718 | 9.13 (7.88, 10.51) | 9.75 (8.11, 10.98) | -0.183 | 0.855 |
| IgA ≥ 4.5 g/L                     | 13.77 (10.00, 29.61) | 12.68 (9.47, 19.70) | 0.353 | 0.725 | 9.75 (7.88, 11.59) | 9.59 (7.88, 10.36) | 0.927 | 0.362 |
| IgG ≥ 16 g/L                      | 15.44 (10.00, 27.44) | 12.14 (9.21, 17.14) | 2.06 | 0.039 | 9.13 (7.88, 10.98) | 9.75 (8.19, 10.36) | -0.59 | 0.555 |
| IgM ≥ 3 g/L                       | 14.05 (10.13, 27.77) | 12.68 (9.47, 19.42) | 0.722 | 0.471 | 10.67 (9.13, 11.59) | 9.44 (7.88, 10.36) | 1.928 | 0.054 |
| C3 < 0.78 g/L                     | 14.33 (11.60, 22.69) | 12.14 (9.47, 19.42) | 1.158 | 0.247 | 9.75 (8.82, 11.59) | 9.13 (7.88, 10.67) | 1.586 | 0.113 |
| C4 < 0.17 g/L                     | 14.88 (12.14, 29.61) | 11.60 (8.95, 18.99) | 2.525 | 0.012 | 9.75 (9.13, 11.59) | 9.44 (7.88, 10.36) | 1.816 | 0.069 |
| ESR ≥ 20 mm/h                      | 13.49 (10.00, 22.90) | 12.68 (9.47, 19.98) | 0.522 | 0.603 | 9.75 (7.88, 11.51) | 9.44 (7.88, 10.36) | 0.996 | 0.321 |
| RF ≥ 20 IU/mL                      | 18.27 (11.06, 32.07) | 10.53 (8.44, 13.77) | 4.407 | <0.001 | 9.75 (8.19, 11.59) | 9.13 (7.88, 10.06) | 2.637 | 0.01 |
| Anti-SSA ≥ 200 RU/mL               | 14.88 (10.00, 25.03) | 10.53 (8.69, 16.71) | 2.375 | 0.018 | 9.59 (8.04, 10.36) | 9.75 (7.88, 11.59) | -0.03 | 0.976 |
| Anti-SSB ≥ 20 RU/mL                | 21.00 (19.95, 23.01) | 19.80 ± 21.39 | 0.304 | 0.762 | 9.95 ± 4.16 | 10.73 ± 3.77 | -1.019 | 0.311 |
| ANA ≥ 1: 320                       | 14.88 (10.00, 29.61) | 11.06 (9.47, 18.27) | 2.132 | 0.033 | 9.44 (8.35, 11.13) | 9.44 (7.88, 10.36) | 0.29 | 0.772 |
| ESSDAI ≥ 5                         | 14.60 (10.53, 22.27) | 10.53 (8.95, 19.42) | 2.109 | 0.035 | 9.44 (7.88, 10.98) | 9.75 (7.88, 10.36) | 0.021 | 0.983 |

with patients with lower autoantibody titers, which further support the positive correlation of IL-17F with pSS associated autoantibody levels. (Table 4).

3.4. IL-17F Was More Relevant with Increased pSS Severity and Disease Activity Than IL-17A. The relationship between pSS clinical and laboratory features and serum IL-17F and IL-17A levels were presented in Table 2, and IL-17F were positively correlated with IgG ($r = 0.026, P = 0.018$) and IgM ($r = 0.215, P = 0.025$) and negatively correlated with C3 ($r = -0.284, P = 0.003$) and C4 ($r = -0.235, P = 0.014$) (Figure 2). However, serum level of IL-17A was only negatively correlated with C3 ($r = -0.304, P = 0.001$) (Figure 3). Besides, patients with elevated IgG decreased C4 and moderate to high disease activity showed significantly elevated serum level of IL-17F. However, elevated serum IL-17A was only observed in patients with increased RF (data shown in Table 4). As shown in Table 3, patients with higher serum levels of IL-17F showed neutropenia, granulocytopenia, elevated IgG, and decreased C3. Increased percentage of patients with moderate to high disease activity (ESSDAI ≥ 5) was found in the group with elevated serum
IL-17F. But pSS patients with higher serum levels of IL-17A showed elevated IgM and decreased C3. Interestingly, as shown in Figure 4, pSS patients with longer disease duration (≥8 years) had significantly elevated levels of IL-17A (Figure 4(a) 11.25 ± 4.70 versus 9.29 ± 2.42, \( P = 0.049 \)). However, there were no differences in IL-17F (Figure 4(b) 21.71 ± 21.79 versus 18.69 ± 19.27, \( P = 0.163 \)) between these two groups.

We also analyzed the correlation between the serum levels of IL-17F and IL-17A and lymph node enlargement,
splenomegaly, joint involvement, lung involvement, RBC, Hb, PLT, IgA, ESR, and anti-SSB antibody and did not find any correlation between them.

These results revealed that it was IL-17F that was more correlated with increased autoantibody level and increased autoimmune conditions such as reduction of C3/4, presence of neutropenia, granulocytopenia, and elevated ESSDAI, instead of IL-17A.

4. Discussion

In this study, we determined and compared the serum levels of IL-17A and IL-17F and found that IL-17F, instead of IL-17A, was significantly increased in serum from pSS patients than in healthy controls. We further revealed their clinical relevance in pSS patients which suggested that different IL-17 family members might play different pathogenic roles in pSS.

Previous studies demonstrated elevated levels of IL-17A in body fluids from pSS patients such as saliva [3–11], tears [4–6, 8], and serum [4, 7, 9], which supported the pathogenic effects of IL-17 axis in pSS. It was reported that IL-17A positive pSS patients had significantly longer disease durations and less prevalent parotid gland swelling compared to those IL-17A negative ones [9]. However, despite its widely accepted pathogenic functions, no correlation between IL-17A and clinical severity or specific extraglandular manifestations has been reported [27]. In this study, we only observed slightly higher level of serum IL-17A in pSS patients compared to healthy controls without statistical significance. IL-17A was only associated with elevated RF and decreased C3 and was
increased disease activity in pSS. The relevance of IL-17A in pSS patients is not remarkable despite its notable pathogenic effects in both animal model and in vitro cell culture systems [2].

Surprisingly, we found that IL-17F, the closest homologue of IL-17A, was significantly elevated in pSS patients and correlated with hyperactivity of humeral autoimmune response, including increased higher IgG, higher IgM, higher levels of RF and higher titers of ANA, and anti-SSA antibody. Furthermore, higher levels of IL-17F were found in patient groups with neutropenia, granulocytopenia, and increased ESSDAI, which indicated that IL-17F was associated with pSS disease activity and severity. Former studies mainly focused on the pathogenic roles of IL-17A in pSS, and after failing to reveal the association between IL-17A and extraglandular involvement, they concluded that IL-17/Th17 might not be involved in clinical manifestations other than glandular impairment [2, 27]. However, involvement of the other IL-17 family cytokines such as IL-17F in autoimmune diseases is still elusive. In this study, for the first time, we revealed that IL-17F was associated with elevated autoimmune level and increased disease activity in pSS.

IL-17F is expressed by Th17 cells and other types of IL-17-expressing T cells such as γδT and NKT in vivo. Many previous studies have described the similar regulation of IL-17A and IL-17F induced by IL-23, TGF-β, IL-6, and IL-21, as well as transcription factors RORyt and STAT3 [23]. Although there are remarkable sequence homology and functional similarity between IL-17A and IL-17F, the mechanism of their difference on biological functions is not fully understood [29]. Wright et al. found that binding affinity of IL-17F to IL-17RA is much lower than that of IL-17A [30] and only IL-17F binds to IL-17RC [31], which suggested that the receptor complexes were differentially engaged by IL-17A and IL-17F. IL-17A is shown to activate all three subgroups of mitogen-activated protein kinases, the extracellular signal-regulated kinases (ERK1 and ERK2), Jun NH2-terminal kinases, and p38 in several cell types, but IL-17F only induces the activation of ERK1/2. Due to its lower affinity, IL-17F seems to be less proinflammatory and IL-17A is more critical than IL-17F in mediating inflammation and autoimmunity, such as in experimental autoimmune encephalomyelitis (EAE) [32]. However, Yang et al. showed IL-17F was more critical than IL-17A in inducing airway inflammation and colitis [23], and Watanabe et al. found IL-17F is a stronger inducer of IL-8 released by keratinocytes and cystic fibrosis, which suggests that IL-17F might play a more prominent role in psoriasis [21, 22]. Moreover, IL-17F is associated with relapse in multiple sclerosis, and IL-17A does not show that correlation, which is quite different from animal models [33]. Similarly, our study found that IL-17F, instead of IL-17A, was significantly correlated with production of autoantibodies and disease activity in pSS. It has been revealed that in several types of tissues, including liver, lung, and ovary, only IL-17F was expressed [14, 34], so the wider tissue distribution of IL-17F might contribute to its involvement in extraglandular pathogenesis in pSS. Recently, Giles et al. discovered that besides IL-17A, IL-17F also played an important role in the driven inflammation of nonalcoholic fatty liver disease [35]. Moreover, IL-17F competed for the receptor with IL-17A and inhibited IL-17A engagement but IL-17F was not inhibited by IL-17A [34]. All these findings support that IL-17F plays a more important pathogenic role in autoimmune disease.

For the first time, we simultaneously examined the serum levels of IL-17A and IL-17F and evaluated and compared their clinical relevance in pSS. Our study demonstrated that serum levels of IL-17F significantly increased in pSS patients and were associated with elevated autoantibody level, more severe autoimmune conditions, and higher disease activity, but IL-17A was only associated with longer disease duration. Our findings suggest that different IL-17 family members might play different roles in the onset and exacerbation of pSS. Further investigations on the exact mechanisms of such discrepancy will provide novel insights into the roles of IL-17 family cytokines in pSS pathogenesis and reveal potential therapeutic value of IL-17 family members.

Competing Interests
The authors declare that they have no competing interests.

Acknowledgments
This work was supported by funds from Ministry of Science and Technology of China (2014BAI07B01, 2014AA020527), National Natural Science Foundation of China (31530020, 81471601, and 81671602), Beijing Natural Science Foundation (7152150), and Beijing Municipal Science & Technology Commission (Z141107002514064).

References
[1] P. Brito-Zerón and M. Ramos-Casals, “Advances in the understanding and treatment of systemic complications in Sjögren’s syndrome,” Current Opinion in Rheumatology, vol. 26, no. 5, pp. 520–527, 2014.
[2] A. Alunno, F. Carubbi, O. Bistoni et al., “T regulatory and Th17 cells in primary Sjögren’s syndrome: facts and perspectives,” Mediators of Inflammation, vol. 2015, Article ID 243723, 10 pages, 2015.
[3] G. E. Katsifis, S. Rekka, N. M. Moutsopoulos, S. Pillemer, and S. M. Wahl, “Systemic and local interleukin-17 and linked cytokines associated with Sjögren’s syndrome immunopathogenesis,” The American Journal of Pathology, vol. 175, no. 3, pp. 1167–1177, 2009.
[4] T. R. Reksten, M. V. Jonsson, E. A. Szyszko, J. G. Brun, R. Jonsson, and K. A. Brostad, “Cytokine and autoantibody profiling related to histopathological features in primary Sjögren’s syndrome,” Rheumatology, vol. 48, no. 9, pp. 1102–1106, 2009.
[5] M. H. Kang, M. K. Kim, H. J. Lee, H. I. Lee, W. R. Lee, and J. H. Lee, “Interleukin-17 in various ocular surface inflammatory diseases,” Journal of Korean Medical Science, vol. 26, no. 7, pp. 938–944, 2011.
[6] S. Y. Lee, S. J. Han, S. M. Nam et al., “Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients
and non-Sjögren syndrome dry eye patients,” *American Journal of Ophthalmology*, vol. 156, no. 2, pp. 247–253, 2013.

[7] Y. Fei, W. Zhang, D. Lin et al., “Clinical parameter and Th17 related to lymphocytes infiltrating degree of labial salivary gland in primary Sjögren’s syndrome,” *Clinical Rheumatology*, vol. 33, no. 4, pp. 523–529, 2014.

[8] X. Tan, S. Sun, Y. Liu et al., “Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome,” *Eye*, vol. 28, no. 5, pp. 608–613, 2014.

[9] A. Alunno, O. Bistoni, S. Caterbi, E. Bartoloni, G. Cafaro, and R. Gerli, “Serum interleukin-17 in primary Sjögren’s syndrome: association with disease duration and parotid gland swelling,” *Clinical and Experimental Rheumatology*, vol. 33, no. 1, p. 129, 2015.

[10] X. Lin, K. Rui, J. Deng et al., “Th17 cells play a critical role in the development of experimental Sjögren’s syndrome,” *Annals of the Rheumatic Diseases*, vol. 74, no. 6, pp. 1302–1310, 2015.

[11] K. Ohyama, M. Moriyama, J.-N. Hayashida et al., “Saliva as a potential tool for diagnosis of dry mouth including Sjögren’s syndrome,” *Oral Diseases*, vol. 21, no. 2, pp. 224–231, 2015.

[12] C. Gu, L. Wu, and X. Li, “IL-17 family: cytokines, receptors and signalling,” *Cytokine*, vol. 64, no. 2, pp. 477–485, 2013.

[13] W. B. van den Berg and I. B. McInnes, “Th17 cells and IL-17—a focus on immunopathogenesis and immunotherapeutics,” *Seminars in Arthritis and Rheumatism*, vol. 43, no. 2, pp. 158–170, 2013.

[14] S. G. Hymowitz, E. H. Filvaroff, J. P. Yin et al., “IL-17’s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17E, and implications for receptor binding,” *The EMBO Journal*, vol. 20, no. 19, pp. 5322–5341, 2001.

[15] J. K. Kolls and A. Lindén, “Interleukin-17 family members and inflammation,” *Immunity*, vol. 21, no. 4, pp. 467–476, 2004.

[16] D. Toy, D. Kugler, M. Wolfson et al., “Cutting edge: interleukin-17 signals through a heteromeric receptor complex,” *The Journal of Immunology*, vol. 177, no. 1, pp. 36–39, 2006.

[17] M. Kawaguchi, M. Adachi, N. Oda, F. Kokubu, and S.-K. Huang, “IL-17 cytokine family,” *The Journal of Allergy and Clinical Immunology*, vol. 114, no. 6, pp. 1265–1273, 2004.

[18] A. G. Shabgah, E. Fattahi, and F. Z. Shahneh, “Interleukin-17 in human inflammatory diseases,” *Postepy Dermatologii i Alerzologii*, vol. 31, no. 4, pp. 256–261, 2014.

[19] J. Gomez-Rodriguez, N. Sahu, R. Hando et al., “Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase,” *Immunity*, vol. 31, no. 4, pp. 587–597, 2009.

[20] T. Starnes, M. J. Robertson, G. Sledge et al., “Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production,” *The Journal of Immunology*, vol. 167, no. 8, pp. 4137–4140, 2001.

[21] H. Watanabe, M. Kawaguchi, S. Fujishima et al., “Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis,” *The Journal of Investigative Dermatology*, vol. 129, no. 3, pp. 650–656, 2009.

[22] S. Fujishima, H. Watanabe, M. Kawaguchi et al., “Involvement of IL-17F via the induction of IL-6 in psoriasis,” *Archives of Dermatological Research*, vol. 302, no. 7, pp. 995–1005, 2010.

[23] X. O. Yang, S. H. Chang, H. Park et al., “Regulation of inflammatory responses by IL-17F,” *The Journal of Experimental Medicine*, vol. 205, no. 5, pp. 1063–1075, 2008.

[24] C. Vitali, S. Bombardieri, R. Jonsson et al., “Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group,” *Annals of the Rheumatic Diseases*, vol. 61, no. 6, pp. 554–558, 2002.

[25] R. Seror, P. Ravaud, S. J. Bowman et al., “EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome,” *Annals of the Rheumatic Diseases*, vol. 69, no. 6, pp. 1103–1109, 2010.

[26] M. Ramos-Casals, P. Brito-Zerón, R. Seror et al., “Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements,” *Rheumatology*, vol. 54, no. 12, pp. 2230–2238, 2016.

[27] A. Alunno, F. Carubbi, E. Bartoloni et al., “Unmasking the pathogenic role of IL-17 axis in primary Sjögren’s syndrome: a new era for therapeutic targeting?” *Autoimmunity Reviews*, vol. 13, no. 12, pp. 1167–1173, 2014.

[28] F. Ciccia, G. Guggino, A. Rizzo et al., “Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren’s syndrome,” *Rheumatology*, vol. 53, no. 7, Article ID keu004, pp. 1313–1320, 2014.

[29] H. Ishigame, S. Kakuta, T. Nagai et al., “Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses,” *Immunity*, vol. 30, no. 1, pp. 108–119, 2009.

[30] J. F. Wright, F. Bennett, B. Li et al., “The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex,” *The Journal of Immunology*, vol. 181, no. 4, pp. 2799–2805, 2008.

[31] R. E. Kuestner, D. W. Taft, A. Haran et al., “Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F,” *The Journal of Immunology*, vol. 179, no. 8, pp. 5462–5473, 2007.

[32] Y. Komiyama, S. Nakae, T. Matsuki et al., “IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis,” *The Journal of Immunology*, vol. 177, no. 1, pp. 566–573, 2006.

[33] Z. Babaloo, M. R. Aliparasti, F. Babaiea, S. Almasi, B. Baradaran, and M. Farhoudi, “The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels,” *Immunology Letters*, vol. 164, no. 2, pp. 76–80, 2015.

[34] M. Kawaguchi, L. F. Onuchic, X.-D. Li et al., “Identification of a novel cytokine, ML-1, and its expression in subjects with non-alcoholic fatty liver disease pathogenesis,” *PLoS ONE*, vol. 11, no. 2, Article ID e0149783, 2016.